Eugenio De Corso, Roberta Anzivino, Jacopo Galli, Silvia Baroni, Walter Di Nardo, Carla De Vita, Antonio Salvati, Chiara Autilio, Stefano Settimi, Dario Mele, Gaetano Paludetti, Joaquim Mullol
OBJECTIVE: The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES). METHODS: We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in monotherapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinorrhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction, difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale...
November 26, 2018: Laryngoscope